2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1530

Vitamin D Deficiency Is Associated With a More Active and Severe Disease In Early Axial Spondyloarthritis: Data From The DESIR Cohort
Abstract Number: 2674

Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy
Abstract Number: 518

Vitamin D In Sjogren’s Syndrome
Abstract Number: 641

Vitamin D Increases The Number and Function Of Myeloid Angiogenic Cells In Systemic Lupus Erythematosus
Abstract Number: 388

Vitamin D Levels and Inflammation In The Aortic Wall Of Patients With Inflammatory Rheumatic Disease and Coronary Artery Disease
Abstract Number: 2192

Vitamin D Receptor Polymorphisms In A Cohort Of Italian Patients With Juvenile Idiopathic Arthritis
Abstract Number: 1121

Volatility Of The Site and Type Of Lesions In The Spine In Patients With Recent Onset Spondyloarthritis and Possible Spondyloarthritis Over a 3-Month Period
Abstract Number: 2156

Weight Change Has A Disease Modifying Effect On Knee Structure and Symptoms In Obese Individuals Without Diagnosed Knee Osteoarthritis
Abstract Number: 452

What Are The Implications Of Concomitant and Pre-Medication On Infusion Reactions To Infliximab: Results From “RemiTRAC Infusion”, a Prospective Real-World Community Registry
Abstract Number: 2098

What Elements Of Physical Therapy Interventions Contribute To Improved Outcomes Following Total Knee Arthroplasty
Abstract Number: 1352

What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Abstract Number: 1511

What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?
Abstract Number: 2287

What Is The Internal Consistency Of The Disease Activity Score (DAS)-28 In Rheumatoid Arthritis Patients Treated In a Real–World Setting?
Abstract Number: 22

WHAT Is The Prevalence Of NON CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN Patients With Antiphospholipid Syndrome?
Abstract Number: 2250

What Is The Real World Relationship Between Patient-Reported Pain Or Patient Global Assessment and Disease Activity Indices In Rheumatoid Arthritis? An Analysis From The Prospective, Observational, Biologic Treatment Registry Across Canada

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].